These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23129048)

  • 1. Genotypic and phenotypic analyses of hepatitis C virus from patients treated with JTK-853 in a three-day monotherapy.
    Ogura N; Toyonaga Y; Ando I; Hirahara K; Shibata T; Turcanu G; Pai S; Yee K; Gerhardt B; Rodriguez-Torres M; Noguchi T
    Antimicrob Agents Chemother; 2013 Jan; 57(1):436-44. PubMed ID: 23129048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical characterization of JTK-853, a novel nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase.
    Ando I; Adachi T; Ogura N; Toyonaga Y; Sugimoto K; Abe H; Kamada M; Noguchi T
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4250-6. PubMed ID: 22615294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor.
    Jiang M; Zhang EZ; Ardzinski A; Tigges A; Davis A; Sullivan JC; Nelson M; Spanks J; Dorrian J; Nicolas O; Bartels DJ; Rao BG; Rijnbrand R; Kieffer TL
    Antimicrob Agents Chemother; 2014 Sep; 58(9):5456-65. PubMed ID: 24982088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.
    Kati W; Koev G; Irvin M; Beyer J; Liu Y; Krishnan P; Reisch T; Mondal R; Wagner R; Molla A; Maring C; Collins C
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1505-11. PubMed ID: 25534735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.
    Troke PJ; Lewis M; Simpson P; Gore K; Hammond J; Craig C; Westby M
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1331-41. PubMed ID: 22203605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
    Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.
    Wang C; Sun JH; O'Boyle DR; Nower P; Valera L; Roberts S; Fridell RA; Gao M
    Antimicrob Agents Chemother; 2013 May; 57(5):2054-65. PubMed ID: 23403428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase.
    Shih IH; Vliegen I; Peng B; Yang H; Hebner C; Paeshuyse J; Pürstinger G; Fenaux M; Tian Y; Mabery E; Qi X; Bahador G; Paulson M; Lehman LS; Bondy S; Tse W; Reiser H; Lee WA; Schmitz U; Neyts J; Zhong W
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4196-203. PubMed ID: 21746939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.
    Voitenleitner C; Crosby R; Walker J; Remlinger K; Vamathevan J; Wang A; You S; Johnson J; Woldu E; Van Horn S; Horton J; Creech K; Shotwell JB; Hong Z; Hamatake R
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5216-24. PubMed ID: 23939896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759.
    Lu L; Mo H; Pilot-Matias TJ; Molla A
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1889-96. PubMed ID: 17371824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.
    Dvory-Sobol H; Voitenleitner C; Mabery E; Skurnac T; Lawitz EJ; McHutchison J; Svarovskaia ES; Delaney W; Miller MD; Mo H
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6599-606. PubMed ID: 25155588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations.
    Fridell RA; Wang C; Sun JH; O'Boyle DR; Nower P; Valera L; Qiu D; Roberts S; Huang X; Kienzle B; Bifano M; Nettles RE; Gao M
    Hepatology; 2011 Dec; 54(6):1924-35. PubMed ID: 21809362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796.
    Howe AY; Cheng H; Johann S; Mullen S; Chunduru SK; Young DC; Bard J; Chopra R; Krishnamurthy G; Mansour T; O'Connell J
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3327-38. PubMed ID: 18559648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Activity of Simeprevir against Hepatitis C Virus Genotype 1 Clinical Isolates and Its Correlation with NS3 Sequence and Site-Directed Mutants.
    Verbinnen T; Fevery B; Vijgen L; Jacobs T; De Meyer S; Lenz O
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7548-57. PubMed ID: 26392483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.
    Le Pogam S; Yan JM; Chhabra M; Ilnicka M; Kang H; Kosaka A; Ali S; Chin DJ; Shulman NS; Smith P; Klumpp K; Nájera I
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5494-502. PubMed ID: 22869576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
    Zhou Y; Bartels DJ; Hanzelka BL; Müh U; Wei Y; Chu HM; Tigges AM; Brennan DL; Rao BG; Swenson L; Kwong AD; Lin C
    Antimicrob Agents Chemother; 2008 Jan; 52(1):110-20. PubMed ID: 17938182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052.
    Wang C; Huang H; Valera L; Sun JH; O'Boyle DR; Nower PT; Jia L; Qiu D; Huang X; Altaf A; Gao M; Fridell RA
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1350-8. PubMed ID: 22214777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistance studies of a dithiazol analogue, DBPR110, as a potential hepatitis C virus NS5A inhibitor in replicon systems.
    Lin HM; Wang JC; Hu HS; Wu PS; Wang WH; Wu SY; Yang CC; Yeh TK; Hsu TA; Jiaang WT; Chao YS; Chern JH; Yueh A
    Antimicrob Agents Chemother; 2013 Feb; 57(2):723-33. PubMed ID: 23165461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b.
    Suzuki F; Sezaki H; Akuta N; Suzuki Y; Seko Y; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Watahiki S; Miyakawa Y; Kumada H
    J Clin Virol; 2012 Aug; 54(4):352-4. PubMed ID: 22658798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JTK-853, a novel non-nucleoside hepatitis C virus polymerase inhibitor, demonstrates a high genetic barrier to resistance in vitro.
    Ando I; Ogura N; Toyonaga Y; Hirahara K; Shibata T; Noguchi T
    Intervirology; 2013; 56(5):302-9. PubMed ID: 24008863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.